Formulation and in-vitro-evaluation of isotretinoin tablets

Journal of Chemical and Pharmaceutical Research

Volumn 4, Issue 5, 2012, Pages 2817-2831

  Ghorab, M M ^a   Mayada Elhadi Babiker, A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Co evaporation; Freeze drying; HP CD; Isotretinoin; Surfactant enriched tablets

Indexed keywords

BINARY SYSTEMS; CO-EVAPORATIONS; COPRECIPITATION METHOD; DISSOLUTION RATES; FREEZE DRYING; IN-VITRO DISSOLUTION; ISOTRETINOIN; MOLECULAR RATIOS; PHYSICAL MIXTURES; TWEEN-20; WATER SOLUBLE DRUGS;

CRITICAL MICELLE CONCENTRATION; DISSOLUTION; SYSTEMS (METALLURGICAL);

SOLUBILITY;

BETA CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; ISOTRETINOIN; POLYSORBATE 20; SURFACTANT;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; EVAPORATION; FREEZE DRYING; IN VITRO STUDY; INFRARED SPECTROSCOPY; PRECIPITATION; SOLUBILIZATION; TABLET FORMULATION; THERMOGRAPHY; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

EID: 84863093376     PISSN: None     EISSN: 09757384     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. A A Elkordy; E A Essab, J. Pharmaceut. Sci, 2010, 6 (1), 3-12.
2. R Liu, Regulatory Aspects of Dissolution for Low Solubility drug products. In: P Sathe; R A Lionberger; S L Lee and L X Yu, Water-insoluble drug formulation 2nd ed., 2007
3. K L Yap; X Liu; J C Thenmozhiyal and P C Ho, Eur. J. Pharm. Sci. 2005, 25, 49-56.
4. A R Dahl; I M Grossi; D P Houchens; L J Scovell; M E Placke; A R Imondi; G D Stoner; L M De Luca; D Wang and J L Mulshine, Clin Cancer Res 2000, 6(8), 2963-2964.
5. M Vogt; M Vertzoni; K Kunath; C Reppas and J B Dressman, Eur. J. Pharm. Biopharm. 2007, 68 (2) 338-345.
6. R G Strickley, pharm. Res. 2004, 21(2), 201-227.
7. T loftsson and M E Brewster, J. Pharm. Sci. 1996, 85(10), 1017-1025.
8. D Attwood and A T Florence, Surface activity. In: Surfactant system: Their Chemistry, Pharmacy and Biology. Chapman and Hall, New York, 1983, pp. 1-4 & 293-387.
9. S B Ruddy; B K Matuszweska; Y A Grim and D E Ostorey, Int. J. pharm. 1999, 182 (2), 173-186.
10. C O Rangel-Yagui; J A Pessoa and L C Tavares, J. Pharm. Pharmaceut. Sci. 2005, 8 (2), 147-163.
11. The British pharmacopoeia (B.P.) 2004. Her Majesty's Stationary office, London, UK, vol.4, pp. A273-A275, A358.
12. The United States pharmacopoeia (USP XXVIII), 2005. 28th ed., the United States Pharmacopeial Convention, Inc., Rockville, MD, USD, pp.2411-2414.
13. M M Ghorab; S A Elkheshen and S H Badr-Eldin, 2008. Pharmaceutical study on certain phosphodiesterase inhibitor. Library of Faculty of pharmacy-Cairo University.
14. P Mura; N Zerrouk; N Mennini; F Maestrelli and C Chemtob, Eur J Pharm Sci. 2003, 19 (1), 67-75.
15. A M Mari{dotless}́a; M B Andriana and I S Adriana, J Therm Anal Calorim 2010, 99, 631-637.
16. H Nakano; T Kiso; K Okamoto; T Tomita; M B Abdul Manan and S Kitahata, J. Biosci. Bioeng. 2003, 95(6), 583-588.
17. E M M Del Valle, Process Biochemistry 2004, 39(9), 1033-1046.
18. R S Hirlekar; S N Sonawane and V J Kadam, Pharm. Sci. Tech. 2009, 10(3), 858-863.
19. T Higuchi and K A Connors, Phase solubility techniques. In: C N Reilly (Ed.). Advances in Analytical and Chemistry Instrumentation, vol. 4, Wiley Inter-science, New York, 1965, pp. 117-212.
20. M S Nagarsenker and M S Josh, Drug Dev. Ind. Pharm. 2005, 31(2), 169-178.
21. R C Rowe; P J Sheskey and M E Quinn, Handbook of Pharmaceutical excipients, sixth edition, 2009
22. O N M Mc Callion; K M G Taylor; M Thomas and A J Taylor, Int. J. pharm. 1999, 129 (1-2), 123-136.
23. A M Khan and S S Shah, J. Chem. SOC. Pak.,2008, 30 (2), 186-191.
24. http://www.chemblink.com/products/4759-48-2.htm
25. J A Ryan, J. Pham. Sci, 1986, 75 (8). 805-807.
26. P Mura; A Manderioli; G Bramanti; S Furlanetto; and S Pinzauti, Int J Pharm. 1995, 119 (1).71-79.
27. A Bocanegra-Diaz; D S W Mohallem and R D Sinisterra, J. Braz. Chem. Soc. 2003, 14 (6). 936-941.